Form 4 Filing for BioStem Technologies, Inc. - Insider Transaction

This filing details a transaction by Mark A. Glickman, a director at BioStem Technologies, Inc. On August 27, 2026, Glickman acquired 7,671 shares of Common Stock through the vesting of 7,671 Restricted Stock Units. The transaction code is "M" and the acquisition/disposal code is "A", indicating an acquisition. The shares were acquired at a price of $0.0 per share, and post-transaction, Glickman holds 7,671 shares. The filing also includes Exhibit 24, a Power of Attorney document, which authorizes Katherine Gorrell and Brandon Poe to act as attorneys-in-fact for Glickman regarding SEC filings and EDGAR account administration. This power of attorney also covers the execution of Forms 3, 4, 5, and 144. The document confirms that Glickman is revoking all previous powers of attorney related to his Section 16 reporting obligations.